Kimberly Rieger-Christ

Dr. Kimberly Rieger-Christ


Research Focus & Metrics

Academic Career Length

26Years (2001-Present)

(Calculated once Scilit publication data is synced: current year − year of first publication + 1)

Representative Publications

View All Publications
15 November 2015
Verified
Journal Article
Closed access
JLJessica De Long
Jessica De Long
TSTravis B Sullivan
Travis B Sullivan
JHJohn Humphrey
John Humphrey
TLTanya Logvinenko
Tanya Logvinenko
KSKelly A Summerhayes
Kelly A Summerhayes
KRKimberly Rieger-Christ
Kimberly Rieger-Christ

1 January 2013 in Genes & Cancer
Verified
Journal Article
Open access
PDF file
SKSpencer I. Kozinn
Spencer I. Kozinn
NHNiall J. Harty
Niall J. Harty
JDJessica M. DeLong
Jessica M. DeLong
CDChristina Deliyiannis
Christina Deliyiannis
TLTanya Logvinenko
Tanya Logvinenko
KRKimberly Rieger-Christ
Kimberly Rieger-Christ
MicroRNAs (miRNA) are small, noncoding RNAs with important regulatory roles in development, differentiation, cell proliferation, and death as well as the complex process of acquired drug resistance. The goal of this study was to identify specific miRNAs and their potential protein targets that confer acquired resistance to gemcitabine in urothelial carcinoma of the bladder (UCB) cell lines. Gemcitabine-resistant cells were established from 6 cell lines following exposure to escalating concentrations of the drug and by passaging cells in the presence of the drug over a 2- to 3-month period. Differential miRNA expression was identified in a microarray format comparing untreated controls with resistant cell lines, representing the maximum tolerated concentration, and results were validated via qRT-PCR. The involvement of specific miRNAs in chemoresistance was confirmed with transfection experiments, followed by clonogenic assays and Western blot analysis. Gemcitabine resistance was generated in 6 UCB cell lines. Microarray analysis comparing miRNA expression between gemcitabine-resistant and parental cells identified the differential expression of 66 miRNAs. Confirmation of differential expression was recorded via qRT-PCR in a subset of these miRNAs. Within this group, let-7b and let-7i exhibited decreased expression, while miR-1290 and miR-138 displayed increased expression levels in gemcitabine-resistant cells. Transfection of pre–miR-138 and pre–miR-1290 into parental cells attenuated cell death after exposure to gemcitabine, while transfection of pre–miR-let-7b and pre–miR-let-7i into the resistant cells augmented cell death. Mucin-4 was up-regulated in gemcitabine-resistant cells. Ectopic expression of let-7i and let-7b in the resistant cells resulted in the down-regulation of mucin-4. These results suggest a role for miRNAs 1290, 138, let-7i, and let-7b in imparting resistance to gemcitabine in UCB cell lines in part through the modulation of mucin-4. Alterations in these miRNAs and/or mucin-4 may constitute a potential therapeutic strategy for improving the efficacy of gemcitabine in UCB.

1 April 2001 in Molecular Pathology
Verified
Journal Article
Open access
PDF file
KRKimberly Rieger-Christ
Kimberly Rieger-Christ
JPJ A Pezza
J A Pezza
JDJ M Dugan
J M Dugan
JBJ W Braasch
J W Braasch
KHK S Hughes
K S Hughes
ISI C Summerhayes
I C Summerhayes
Aims—The relation between lobular carcinoma in situ (LCIS) and invasive breast cancer is unresolved. In an attempt to establish whether LCIS is a precursor of invasive cancer the mutational status and the expression of E-cadherin was analysed in LCIS and associated invasive breast carcinoma in 23 patients. Methods—Foci of LCIS and associated invasive carcinoma were individually microdissected from tissue from 23 patients. Exons 4–16 of the E-cadherin gene were analysed using single strand conformation polymorphism (SSCP); protein expression and the localisation of E-cadherin and β-catenin were assessed with the use of immunohistochemistry. Results—Immunohistochemistry revealed a lack of expression of E-cadherin and β-catenin in most LCIS samples and invasive foci. In all but four cases, the staining pattern was identical in the LCIS and associated invasive areas. When E-cadherin was absent, β-catenin was also undetected, suggesting a lack of expression of alternative classic cadherin members in these lesions. Coincident E-cadherin mutations in LCIS and associated invasive carcinoma were not identified in this series of patients. However, mutational analysis of E-cadherin in multiple foci of carcinoma in situ surrounding an invasive lesion provided evidence to support ductal carcinoma in situ as a precursor of invasive ductal carcinoma. Conclusion—These data support the hypothesis that LCIS is not a precursor of invasive breast carcinoma but a marker of increased risk of developing invasive disease.

1 January 2018 in Neural Regeneration Research
Verified
Journal Article
Open access
PDF file
KRKimberly Rieger-Christ
Kimberly Rieger-Christ
TSTravis B Sullivan
Travis B Sullivan
LRLitchfield C Robert
Litchfield C Robert
PTPatrickA Teebagy
PatrickA Teebagy
SMShannonE Morgan
ShannonE Morgan
DBDavid J Bryan
David J Bryan
While the peripheral nervous system has regenerative ability, restoration of sufficient function remains a challenge. Vimentin has been shown to be localized in axonal growth fronts and associated with nerve regeneration, including myelination, neuroplasticity, kinase signaling in nerve axoplasm, and cell migration; however, the mechanisms regulating its expression within Schwann cell (SC) remain unexplored. The aim of this study was to profile the spatial and temporal expression profile of microRNA (miRNA) in a regenerating rat sciatic nerve after transection, and explore the potential role of miR-138-5p targeting vimentin in SC proliferation and migration. A rat sciatic nerve transection model, utilizing a polyethylene nerve guide, was used to investigate miRNA expression at 7, 14, 30, 60, and 90 days during nerve regeneration. Relative levels of miRNA expression were determined using microarray analysis and subsequently validated with quantitative real-time polymerase chain reaction. In vitro assays were conducted with cultured Schwann cells transfected with miRNA mimics and assessed for migratory and proliferative potential. The top seven dysregulated miRNAs reported in this study have been implicated in cell migration elsewhere, and GO and KEGG analyses predicted activities essential to wound healing. Transfection of one of these, miRNA-138-5p, into SCs reduced cell migration and proliferation. miR-138-5p has been shown to directly target vimentin in cancer cells, and the luciferase assay performed here in rat Schwann cells confirmed it. These results detail a role of miR-138-5p in rat peripheral nerve regeneration and expand on reports of it as an important regulator in the peripheral nervous system.

11 May 2024 in Cancers
Verified
Journal Article
Open access
PDF file
SMShannon McNall
Shannon McNall
KHKailey Hooper
Kailey Hooper
TSTravis Sullivan
Travis Sullivan
KRKimberly Rieger-Christ
Kimberly Rieger-Christ
MCMatthew Clements
Matthew Clements
The landscape of treatment for non-muscle invasive bladder cancer is rapidly changing. A complete and careful transurethral resection is the mainstay of initial treatment and is followed by intravesical therapy in intermediate or high-risk cases. The standard of care is intravesical BCG. Many alternative or additive approaches to this are being explored. We divided this review into three relevant spaces to consider these novel treatment approaches: (1) low-risk disease, for which intravesical therapy is not usually considered, (2) BCG-naïve disease (i.e., considering alternatives to the standard therapy), and (3) BCG-unresponsive disease. We performed a review of published literature and summarized ongoing trials in the United States. Novel approaches that we explored include surgical techniques for resection, alterations in dwell time for intravesical therapy, delivery method and schedule of intravesical therapies, new intravesical therapy agents, and systemic therapies (especially immunotherapy). These are thoroughly outlined throughout this review article, and the numerous modalities being studied demonstrate significant promise for the future treatment of the expanding space of NMIBC.

18 May 2017 in BJU International
Verified
Journal Article
Closed access
PDF file
CKCasey G. Kowalik
Casey G. Kowalik
DPDrew A. Palmer
Drew A. Palmer
TSTravis B. Sullivan
Travis B. Sullivan
PTPatrick A. Teebagy
Patrick A. Teebagy
JDJohn M. Dugan
John M. Dugan
KRKimberly Rieger-Christ
Kimberly Rieger-Christ